Sirtex announces SIR-Spheres®
portfolio expansion to include the FLEXdose SELECT 3mL vial
configuration allowing for more patient-specific Y-90 selective treatment plans
WOBURN,
Mass., Aug. 5, 2024 /PRNewswire/ -- Sirtex
Medical ("Sirtex"), a leading manufacturer of interventional
treatment solutions, announced today the launch of its
SIR-Spheres® FLEXdose SELECT Delivery Program, an
innovative, new way to offer precise Y-90 selective internal radiation therapy for the
treatment of metastatic colorectal cancer.
SIR-Spheres® FLEXdose SELECT Delivery Program
offers unparalleled flexibility by enabling tailored,
patient-specific dosing from a single 3mL delivery vial. This
program also marks the availability of 3mL SIR-Spheres®
vials, which contain a reduced volume of microspheres
(approximately 27 million compared to 44 million in the current 5mL
vials). With up to five days pre-calibration available every day of
the week, the novel Y-90 delivery
program offers a vial of SIR-Spheres® designed for more
selective treatment targeting.
"We're pleased to introduce this latest innovation in
Y-90 radioembolization therapy to
treat a broader spectrum of tumor burden," said Matt Schmidt, CEO of Sirtex Medical Limited.
"The SIR-Spheres® FLEXdose SELECT Delivery Program
reflects our continued focus on listening to the needs of patients
and physicians by enabling access to personalized Y-90 resin doses and expedited patient
treatments."
"I have found the SIR-Spheres® FLEXdose Program to be
extremely helpful in treating my patients on a timely basis,"
explained Ripal Ghandi, M.D., a
member of the Miami Cardiac & Vascular Institute and Miami
Cancer Institute and the course director for the Symposium on
Clinical Interventional Oncology. "With this program, I can
personalize the Y-90 treatment for
each of my patients using a product that is available every day of
the week. I applaud Sirtex for investing resources in
SIR-Spheres® FLEXdose SELECT and providing more
options for physicians to optimize treatment strategies for even
more patients."
The new 3mL SIR-Spheres® Y-90 resin microspheres
vials are available for order at csusa@sirtex.com. For more
information and details on how to incorporate the
SIR-Spheres® FLEXdose SELECT Delivery Program into your
practice, please contact Sirtex at info-use@sirtex.com.
About SIR-Spheres
SIR-Spheres® are a
medical device used in selective internal radiation therapy).
SIR-Spheres® are indicated for the treatment of
unresectable metastatic liver tumors from primary colorectal cancer
with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR
(Floxuridine).
Caution: Federal (USA) law
restricts this device for sale by or on the order of a physician.
Consult the Instructions for Use (www.sirtex.com) for a
complete listing of indications, contraindications, side effects,
warnings and precautions.
About Sirtex
Sirtex is a global healthcare business
with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people
with cancer. Sirtex's current lead product is a targeted radiation
therapy for liver cancer called SIR-Spheres®
Y-90 resin microspheres. For more
information, visit www.sirtex.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sirtex-medical-launches-sir-spheres-flexdose-select-delivery-program-to-enable-more-selective-y-90-treatment-plans-302214411.html
SOURCE Sirtex Medical Inc.